sc262
Large B-cell Lymphoma
Sana BiotechnologyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
71 Active assets in the Large B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axicabtagene Ciloleucel Zhejiang Cancer Hospital | Phase 4 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Fludarabine M.D. Anderson Cancer Center | Phase 4 | BB |
ETOPOSIDE University of California, Davis | Phase 2/3 | BB |
Inno-206 Ruijin Hospital | Phase 3 | BB |
View all 50 →
Same molecule, other indications
sc262 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →